The concern of generic rivalry has consistently loomed above copyright’s iconic drug, Sildenafil, sparking questions about the outlook of connected medicinal investments. While early years saw impressive returns, the intellectual property end has allowed the path for discounted alternatives, likely lowering earnings and posing a significant dange